Therapy-Related Myelodysplastic Syndromes in an Ovarian Carcinoma Patient Following Treatment with Paclitaxel- and Carboplatin-Based Regimens

• Published in: JOURNAL OF THE JAPANESE ASSOCIATION OF RURAL MEDICINE Vol. 57; no. 6; pp. 873 - 877
• Main Authors: MURAKAMI, Masahiro, IKAWA, Hiroshi
• Format: Journal Article
• Language: Japanese
• Published: THE JAPANESE ASSOCIATION OF RURAL MEDICINE 30.03.2009
• Subjects: myelodysplasia syndrome (MDS); ovarian canser; paclitaxel
• ISSN: 0468-2513; 1349-7421
• DOI: 10.2185/jjrm.57.873

Progress in chemotherapeutic strategy has significantly decreased side effects of the drugs used and greatly added to survival rates for ovarian cancer. On the other hand, the occurrence of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) has been reported after long-term chemotherapy. We encountered a case of therapy-related MDS that developed as a consequence of chemotherapy. A 59-year-old woman (gravida 2, para 2) stage IIIc ovarian cancer received three courses of paclitaxel and carboplatin therapy (TC) prior to primary surgery, and 16 courses of weekly TC as adjuvant chemotherapy. She exhibited pacritaxel-associated hypersensitivity reactions in the last course, so that chemotherapy was discontinued. Following three mouths of remission, a sudden rise in her tumor markers and an increase in the size of her pelvic lymphonode were discovered on PET-CT. She recieved multiple courses of chemotherary of docetaxel/carboplatin, weekly docetaxel, docetaxel/briplatin and Gemcitabin/Irinotecan between four months. In 30 months after diagnosis, complete blood count showed hemoglobin 7.7 g/dl; white cell count 4,310/μl; and platelet 7.9×104/μl. A bone marrow examination revealed MDS. She then decided against further chemotherapy, opting instead for palliative care. Fortunately, up to the present, she has not developed AML.